Information for COVID-19 Therapeutics Providers
This page contains information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact therapeutics@dshs.texas.gov or call Provider Support at 833-832-7068, option 0.
On this page:
- News & Updates
- How to Become a COVID-19 Therapeutics Provider
- Therapeutics Products
- Important Links
- Texas COVID-19 Product Availability
- Job Aids & FAQs
- Webinars
- Billing & Coding Information
News & Updates
Evusheld No Longer Authorized as of 01/27/23
Evusheld (tixagevimab co-packaged with cilgavimab) is no longer authorized by the FDA for use in the United States, effective immediately. See the 01/27/23 DSHS letter to therapeutics providers for complete details.
Bebtelovimab No Longer Authorized as of 11/30/22
Bebtelovimab is no longer authorized by the FDA for use in the United States, effective immediately. See the 11/30/22 DSHS letter to therapeutics providers for complete details.
Weekly eDigests (PDFs)
- 01/23/23 Weekly eDigest: NEW: Information Sheet: Key Messages for Long Term Care Facilities; Reminder: Variants and Evusheld Resistance Updates; NEW: Therapeutics Information Sheets; Reminder: Shelf-Life Extensions; etc.
- 01/16/23 Weekly eDigest: NEW: Variants and Evusheld Resistance Updates; NEW: Therapeutics Information Sheets; NEW: Walgreens Expands Home Delivery to include Lagevrio; NEW: Legislative Provision to Allow Part D payment of EUA oral antivirals if commercialized while under EUA; New and Updated Resources: Lagevrio Information Sheet, Digital Toolkit, and CDC Webpages; Reminder: Shelf-Life Extensions; etc.
How to Become a COVID-19 Therapeutics Provider
To enroll as a therapeutics provider, please email therapeutics@dshs.texas.gov or call Provider Support at 833-832-7068, option 0.
Therapeutics Products
Click on any of the buttons below to access a list of product-specific resources.
Shelf-life extension information can be found individually in each of the applicable product-specific sections, as well as in the Shelf-Life Extensions section below.
For the latest information on product distribution across the state, see the Texas COVID-19 Product Availability section.
Monoclonal Antibody (mAb) Products
Bamlanivimab + Etesevimab (Lilly) Casirivimab + Imdevimab (Regeneron) Sotrovimab (GlaxoSmithKline) Bebtelovimab (Lilly)
Long-Acting Antibody (LAAB) Product
Evusheld: tixagevimab + cilgavimab (AstraZeneca)
Oral Antiviral Products
Lagevrio (molnupiravir) (Merck) Paxlovid: nirmatrelvir + ritonavir (Pfizer)
Shelf-Life Extensions
- Bebtelovimab shelf-life extended (ASPR)
- Shelf-Life Extension for Bamlanivimab (ASPR)
- Shelf-Life Extension of Bamlanivimab and Etesevimab
- Shelf-Life Extension for REGEN-COV (ASPR)
- Shelf-Life Extension for Sotrovimab (ASPR)
- Shelf-Life Extension for Evusheld (ASPR)
- Shelf-Life Extension for Paxlovid
Important Links
- Health Partner Order Portal (HPOP) Provider Sign In
- COVID-19 Treatment Guidelines: Anti-SARS-CoV-2 Monoclonal Antibodies (NIH)
- NIH Statement on Therapies for High-Risk, Nonhospitalized Patients
- NIH Statement on Patient Prioritization for Outpatient Therapies
- NIH Statement on Evusheld for Pre-Exposure Prophylaxis
- SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests (FDA)
- COVID-19 Therapeutics (ASPR)
- Side-by-Side Overview of COVID-19 Therapeutics (ASPR)
- Comparison of Outpatient Therapies Effective Against Omicron Variant (TMA)
- COVID-19 Therapeutics Decision Aid (ASPR)
Texas COVID-19 Product Availability
- U.S. HHS COVID-19 Public Therapeutic Locator
- U.S. HHS Oral Antiviral Location Finder – including Test to Treat sites.
Job Aids & FAQs
- Therapeutics Product Guide – Job Aid (PDF, updated 6/17/2022)
- FAQs for Therapeutics Providers (PDF, V.8.0, updated 10/27/2022)
Webinars
- DSHS Evusheld Webinar (2/11/2022): Dosage updated since webinar was recorded. Please see Evusheld Fact Sheet for Healthcare Providers for current dosage and indications.
- CDC COCA Call (6/16/2022): What Clinicians Need to Know About Available Therapeutic Options for COVID-19
- Weekly calls with US HHS/ASPR Therapeutics Team: Email COVID19Therapeutics@HHS.gov to request invitations and links.
- Allocation, Distribution, Administration of COVID-19 Therapeutics: Wednesdays, 2:15–3:15 PM central
- COVID-19 Therapeutics Weekly Clinical Rounds: Fridays, 11:00 AM–noon central
Billing & Coding Information
- Centers for Medicare and Medicaid Services Provider Toolkit
- COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing
- CMS Monoclonal Antibody COVID-19 Infusion
- CMS Oral Antiviral Guidance
- CMS Medicare Part B Payment for COVID-19 Vaccines and Certain Monoclonal Antibodies
- U.S. HRSA COVID-19 Claims Reimbursement for Testing, Treatment, and Vaccine for the Uninsured
This page is being updated as new information becomes available.